WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016 by Kobayashi, Miwako et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2016
WHO consultation on group B Streptococcus
vaccine development: Report from a meeting held
on 27–28 April 2016
Miwako Kobayashi
Centers for Disease Control and Prevention
Stephanie J. Schrag
Centers for Disease Control and Prevention
Mark R. Alderson
Center for Vaccine Innovation and Access
Shabir A. Madhi
University of the Witwatersrand, Johannesburg
Carol J. Baker
Baylor College of Medicine
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Kobayashi, Miwako; Schrag, Stephanie J.; Alderson, Mark R.; Madhi, Shabir A.; Baker, Carol J.; Sobanjo-ter Meulen, Ajoke; Kaslow,
David C.; Smith, Peter G.; Moorthy, Vasee S.; and Vekemans, Johan, "WHO consultation on group B Streptococcus vaccine
development: Report from a meeting held on 27–28 April 2016" (2016). Public Health Resources. 513.
http://digitalcommons.unl.edu/publichealthresources/513
Authors
Miwako Kobayashi, Stephanie J. Schrag, Mark R. Alderson, Shabir A. Madhi, Carol J. Baker, Ajoke Sobanjo-
ter Meulen, David C. Kaslow, Peter G. Smith, Vasee S. Moorthy, and Johan Vekemans
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/
publichealthresources/513
WHO consultation on group B Streptococcus vaccine development:
Report from a meeting held on 27–28 April 2016
Miwako Kobayashi a,b, Stephanie J. Schrag a, Mark R. Alderson c, Shabir A. Madhi d, Carol J. Baker e,
Ajoke Sobanjo-ter Meulen f, David C. Kaslow c, Peter G. Smith g, Vasee S. Moorthy h, Johan Vekemans h,⇑
aNational Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329-4027, USA
b Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
cCenter for Vaccine Innovation and Access, PATH, Seattle, WA 98121, USA
dDepartment of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, and Medical Research Council: Respiratory and Meningeal Pathogens
Research Unit, University of the Witwatersrand, Johannesburg, South Africa
eDepartment of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
fBill & Melinda Gates Foundation, Seattle, WA 98109, USA
gMRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK
h Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland
a r t i c l e i n f o
Article history:
Available online xxxx
Keywords:
Group B Streptococcus
Maternal vaccination
Phase III trial
Vaccine licensure
a b s t r a c t
Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the
first 90 days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting
GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many
high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low.
Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting
newborns and young infants, through transplacental antibody transfer and potentially by reducing
new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential
GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for
Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vac-
cine for maternal immunization because of the major public health burden posed by GBS in LMICs, and
the high technical feasibility for successful development. Following this meeting, the first WHO technical
consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development path-
ways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and
possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps
in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under devel-
opment; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommen-
dations and use. Efforts to address gaps identified in each of these areas are needed to establish the
public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more
work is required to understand the global disease burden of GBS-associated stillbirths, and to develop
quality-assured standardized antibody assays to identify correlates of protection.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction and objectives
In 2014, the World Health Organization (WHO) convened the
first meeting of the Product Development for Vaccines Advisory
Committee (PDVAC). The committee was given the remit to review
the status of vaccines under development, whose licensure and use
may contribute importantly to reducing the disease burden in low-
and middle-income countries (LMICs). At the meetings of the com-
mittee in 2014 and 2015 the status of vaccine development against
18 pathogens was reviewed [1]. At these meetings Respiratory
Syncytial Virus (RSV) and group B Streptococcus (GBS) were identi-
fied as important pathogens causing a large burden of disease
among neonates and infants in LMICs that may be amenable to
prevention by immunization, including by maternal vaccination
in pregnancy [1].
On the 27th and 28th of April 2016, WHO convened their first
technical consultation on GBS vaccines, with participants drawn
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from academia, industry, public health agencies, funding bodies
and regulatory authorities. Discussions focused on the develop-
ment of GBS vaccines for maternal immunization, with emphasis
on specific needs in LMICs. Topics discussed included: (1) patho-
physiology of GBS disease; (2) current gaps in the knowledge of
global GBS disease burden and serotype distribution; (3) vaccine
products under development; (4) design considerations for phase
III trials; and (5) pathways to licensure, policy recommendation
and use.
2. GBS pathophysiology and disease syndromes, basic
bacteriology
Neonatal and young infant GBS disease can be classified into
early-onset disease (EOD, onset during the first 6 days of life),
and late-onset disease (LOD, onset between days 7–89 of life). It
is estimated that 60–90% of EOD occurs on the first day of life
[2,3]. GBS colonizes the human gastrointestinal and genitourinary
tracts, and throat, and vertical transmission from colonized moth-
ers can lead to invasive disease in their offspring. Disease in neo-
nates and young infants develops as a result of invasion of GBS
across epithelial cells into the bloodstream [4]. HIV-exposed
infants are at a higher risk of developing invasive GBS disease [2,5].
GBS has also been associated with stillbirths and prematurity,
through mechanisms that remain poorly understood [6,7]. Addi-
tionally, during pregnancy and postpartum, women are at
increased risk of developing invasive GBS disease [8].
GBS produces a polysaccharide capsule of 10 antigenic types (Ia,
Ib, II, III, IV, V, VI, VII, VIII, IX). In 1976, it was reported that
transplacental transfer of maternal antibodies to type III capsular
polysaccharide (CPS) was associated with protection against CPS
type III GBS invasive disease in infants [9]. Results from subsequent
studies supported this finding and generalized this to other GBS
serotypes [10–13], providing a rationale for maternal GBS vaccina-
tion targeting CPS to prevent disease in young infants.
Proteins such as alpha-C-protein (bca), C alpha-like proteins 2
and 3 (alp2 and alp3), epsilon/Alp1, Rib (rib), and beta-C-protein
(bac) are embedded in the GBS bacterial surface, and are also can-
didate vaccine targets.
3. GBS disease management and prevention practices
WHO currently recommends intrapartum antibiotic prophy-
laxis (IAP) administered intravenously for women with GBS colo-
nization to prevent early neonatal GBS infection, but
acknowledges that systematic GBS screening may not be feasible
in many settings, and the presence of other risk factors should be
considered [14]. IAP is recommended for women with preterm
pre-labour rupture of membranes, but not for women in preterm
labour with intact amniotic membranes, nor for women with
pre-labour rupture of membranes at term or near term (36 weeks
gestation and above). The latter is based on evidence from studies
including women with membrane rupture duration under 12 h,
and it is acknowledged that there may be a benefit from IAP in
women with prolonged rupture of membranes (>18 h) [14].
High income countries that have implemented IAP select preg-
nant women for treatment by either screening for GBS colonization
or by monitoring them for known intrapartum risk factors. South
Africa, an upper-middle income country, has introduced a risk-
based IAP strategy, but with limited uptake [15]. A multiplicity of
access to care and health system challenges complicate the imple-
mentation of IAP in many LMIC settings.
For neonates and young infants, WHO recommends empirical
treatment with ampicillin and gentamicin at birth for all
high-risk neonates (membranes ruptured > 18 h before delivery,
maternal fever before delivery and during labour, foul-smelling
or purulent amniotic fluid) [16]. However, many countries, partic-
ularly those in sub-Saharan Africa, experience challenges in imple-
menting these recommendations.
WHO currently recommends that pregnant women have at
least four antenatal visits to a health care facility, but in many
LMICs the actual number of visits is less [17]. Nevertheless, more
than 80% of pregnant women in sub-Saharan Africa make at least
one antenatal care visit, providing an opportunity for administer-
ing maternal vaccination, if the visits occur with sufficient time
prior to delivery for a protective immune response to develop. That
said, the proportion of women making at least one antenatal visit
varies widely between countries (e.g., in 2014 from 41% in Ethiopia
to 99% in Swaziland) [18].
4. Global GBS disease burden
In a global meta-analysis, countries in the WHO Africa region
had the highest pooled estimate of young infant (day 0–89)
invasive GBS disease (pooled incidence 1.21/1000 livebirths, 95%
CI: 0.50–1.91) [19]. In a more recent systematic review, focusing
on data from sub-Saharan African countries, it was estimated that
the incidence may be twice as high [20]. The lowest pooled esti-
mate in the global review was reported for Southeast Asia (pooled
incidence 0.02/1000 livebirths, 95% CI: 0.00–0.07) [19]. It is unclear
why the burden of GBS disease appears to be low in this region and
more rigorous studies in Southeast Asia are needed to determine if
this is due to under-ascertainment or to true differences in the
incidence of GBS disease in this region.
In an analysis of the global distribution of GBS, five serotypes
(Ia, Ib, II, III, V) accounted for 94% of invasive disease in young
infants [19]. A limitation of this analysis is that there were no ser-
otype data reported from Southeast Asia and only two studies from
the African region. Recent reports from Kenya and The Gambia
showed that these five serotypes were also the most frequent
[21,22]. Data from Central Africa are sparse. Limited serotype data
from Southeast Asia suggest that there might be variations in ser-
otype distribution within regions [23]. The CC17 hypervirulent
clone has classically been restricted to the type III serotype but
capsular switching and possible emergence of a hypervirulent type
IV serotype has been reported [24].
Data on the global burden of GBS-related stillbirths are sparse.
In a recent systematic review, the proportion of stillbirths associ-
ated with GBS infection ranged from 0 to 12%. However, the
paucity of data and lack of standardized case definitions for
stillbirths limited the conclusions that could be drawn [25].
Two recent, rigorously conducted prospective studies of still-
births in Kenya [21] and South Africa [Madhi et al., in progress]
found that the incidence of GBS-associated stillbirths was similar
to or exceeded that of invasive EOD in their respective settings.
These studies, which included culture of GBS from either cord
blood or blood obtained from heart-puncture, suggest that GBS
associated stillbirth might be part of the continuum of the clini-
cal spectrum of EOD, in which the majority of cases present at
birth.
Accurate estimates of the GBS disease burden in LMICs are dif-
ficult to obtain for a number of reasons, including: (1) failure to
obtain specimens in high neonatal mortality settings, particularly
immediately after and within the first 24 h of birth when most
EOD occurs; (2) limited GBS recovery from specimens that are col-
lected and processed through suboptimal methods; (3) the fre-
quent initiation of antibiotic therapy before specimen collection
and (4) absence of denominator data for incidence estimates.
Unfortunately, regions with the highest burden of neonatal deaths
are those most impacted by these problems.
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Data about young infant GBS disease in high income countries
(HICs) further support the need for a vaccine. The United States
(US) recommends universal screening and IAP in all colonized
women. The first consensus guideline for the prevention of perina-
tal invasive GBS disease was issued in 1996, resulting in a greater
than 80% reduction in EOD [26]. However, IAP did not lead to
reductions in the incidence of LOD [26], and there are still approx-
imately 2000 cases annually of young infant invasive GBS disease
in the US. Moreover, over 30% of neonates delivered in the US are
exposed to intrapartum antibiotics, raising concerns about the
effects of such use on antimicrobial resistance and the potential
impact on the newborn’s microbiome. European countries have
adopted a range of screening and risk-based approaches to GBS
prevention. Despite these, GBS remains the leading cause of bacte-
rial meningitis in young infants [27], with significant mortality and
long-term morbidity. Recently some countries, including the
Netherlands [28] and the United Kingdom [29], have reported
increases in both EOD and LOD. Data from both the US and Europe
indicate that the distribution of serotypes causing young infant
disease has been relatively stable over time, with over 90% of cases
attributable to serotypes Ia, Ib, II, III, and V [30–32].
5. GBS vaccine candidates
Currently, CPS conjugate vaccines and protein-based GBS vacci-
nes are under development. The conjugate vaccines use GBS CPS as
the primary target and enhance immunogenicity by covalent con-
jugation of a protein carrier, such as tetanus toxoid or CRM197 (a
non-toxic mutant of diphtheria toxin). Development of these prod-
ucts builds on a history of successfully licensed conjugate vaccines
for Haemophilus influenzae type b (Hib), Neisseria meningitidis, and
Streptococcus pneumoniae, shown to protect vaccinated individuals
against disease and to prevent acquisition of bacterial carriage,
leading to herd immunity. Some limitations of multivalent conju-
gate vaccines include their complex manufacturing process,
reflected in their pricing, and the fact that they confer protection
only against included serotypes. Protein vaccines use common
GBS protein(s) as the vaccine target, and have the potential to con-
fer broad protection across serotypes. In addition, they may be less
complex and less expensive to manufacture. However, the rela-
tionship between antibodies against surface proteins and develop-
ment of disease has not been established.
Maternal vaccination of mice followed by challenge of neonatal
pups has frequently been used to evaluate GBS vaccine candidates
[33,34]. Such models can shed light on the functional activity of
immunogens, such as specific protein antigen targets [35,36]. They
can also contribute to understanding of disease pathophysiology
and study of factors leading from colonization to invasion
[37–39]. Animal reproductive toxicology studies are typically
required before evaluation in pregnant women.
GlaxoSmithKline (GSK) (previously Novartis) has sponsored
phase I and II trials of an investigational trivalent (Ia, Ib, III)
CPS-CRM197 GBS conjugate vaccine, and are currently pursuing
pre-clinical studies of a pentavalent (Ia, Ib, II, III, V) CPS-CRM197
vaccine. Their vaccine is being developed for immunization in
pregnancy to prevent subsequent invasive GBS disease in neonates
and young infants. A total of 1732 non-pregnant women and 610
pregnant women have been vaccinated with the trivalent vaccine
in phase I/II trials. The vaccine was well-tolerated, with no safety
signals of concern in either mothers or infants. Reported local
and systematic reactions were mostly mild to moderate, and no
vaccine-related serious adverse events were reported. Over 75%
of both non-pregnant and pregnant vaccine recipients
demonstrated a more than four-fold rise in serotype-specific IgG
concentrations, and mother to infant IgG transfer rates were
50–81% across all serotypes, similar to that observed with other
polysaccharide conjugate vaccines [40–43]. CPS-specific antibody
concentrations in infants of vaccinated mothers remained, for at
least 90 days, above that of infants whose mothers were adminis-
tered placebo. There was no evidence of an enhanced immune
response with two vaccine doses compared to one, or with the
use of aluminum hydroxide adjuvant [41], or of interference with
responses to infant diphtheria vaccination [40]. However, vaccine
responses were lower among women with no detectable anti-
GBS IgG at baseline and among HIV-infected women [43].
Pfizer is also in early phase development with a candidate CPS-
CRM197 vaccine for the prevention of GBS invasive disease in
infants, through maternal immunization during pregnancy. This
vaccine is being developed using the platform developed for other
conjugate vaccines (e.g., 13-valent pneumococcal conjugate
vaccine).
MinervaX is investigating a protein-based vaccine candidate,
based upon a fusion protein of the N-terminal domains of Alpha-
like proteins, Rib and AlpC (GBS-NN). Alpha-like proteins are a
family of GBS surface proteins which are found on almost all GBS
isolates analyzed to date. Preliminary findings in a case-control
epidemiologic study indicated that antibodies against full-length
AlpC and Rib transfer efficiently across the placenta, and low anti-
body concentrations to AlpC and Rib in neonates correlated to
increased susceptibility to invasive GBS infection caused by strains
expressing Rib [44]. Minervax has completed phase Ia studies with
GBS-NN in non-pregnant female volunteers, and a phase Ib study is
underway among non-pregnant women to test for safety and dose-
confirmation. Results to date have shown favourable safety and
immunogenicity of GBS-NN in non-pregnant women. The current
strategy is based on a one- or two-dose vaccine schedule with alu-
minum hydroxide adjuvant, for administration early in the third
trimester of pregnancy. Further studies on correlates of protection
and maternal transfer of naturally occurring GBS-NN antibodies
are ongoing.
6. GBS vaccine development considerations for LMICs
There are several obstacles to research on, and ultimately
deployment of, GBS vaccines in LMICs, including infrastructure
challenges, limited financial resources, health systems deficiencies,
and limited regulatory experience for product licensure. However,
public-private partnership initiatives and innovative financing
mechanisms can help to overcome these and several capacity
strengthening initiatives are ongoing. PATH’s Center for Vaccine
Innovation and Access aims to accelerate the development of vac-
cines that will be effective and affordable in the countries that
most urgently need them [45]. Their GBS vaccine programme
focuses on working with developing country vaccine manufactur-
ers to develop a polyvalent GBS conjugate vaccine.
The only published analysis of the economic impact of imple-
menting GBS vaccines in LMICs is by Kim and colleagues for South
Africa [46]. With the assumption of 10–30 USD/dose of vaccine
(which is well above the classical GAVI procurement price range),
vaccine efficacy against included serotypes of 50–90% among term
infants, with lower efficacy among preterm infants, and vaccine
coverage of 75%, maternal immunization was assessed to be very
cost effective (range 416–3545 USD/DALY averted). A cost-
effectiveness analysis for GAVI-eligible countries in sub-Saharan
Africa is currently being conducted by Sinha and colleagues. There
is a need for further work on the impact and cost-effectiveness of
candidate GBS vaccines, especially focusing on low income set-
tings, taking into account recent data on the role of GBS on still-
births. Cost-effectiveness models for HICs need to be updated
taking into account current disease trends.
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7. Regulatory considerations
While, to our knowledge, no vaccine has so far obtained regula-
tory approval for labeling for use during pregnancy, several vacci-
nes are recommended for use during pregnancy by public health
authorities, and progress is being made in the regulatory pathway
to vaccine licensure for use in pregnancy [47]. Clinical develop-
ment can be overseen in the United States by the investigational
new drug (IND) programme, possibly followed by a Biological
License Application. In Europe, a Marketing Authorisation request
can be submitted to the European Medicine Agency (EMA). The
EMA can also conduct a regulatory review for products intended
for use outside Europe through the Article 58 pathway. Submis-
sions for registration can be made as specified by relevant national
regulatory authorities in LMICs. For sub-Saharan African countries,
the African Vaccine Regulatory Forum (AVAREF) has played a key
role in facilitating timely regulatory authorization and approvals
of group A meningococcal conjugate vaccine (MenAfriVac)
through its joint reviews. AVAREF also has a track record of facili-
tating clinical trial authorization at the pre-licensure stage [48].
The Developing Country Vaccine Regulators’ Network (DCVRN)
may also facilitate steps in regulatory processes in LMICs [49].
Studies to demonstrate the clinical benefit of new vaccines are
generally required by regulators, either pre- or post-licensure. Piv-
otal data to support licensure could be derived from a randomized,
double-blind placebo-controlled trial, with a relevant GBS disease
entity as primary endpoint. Regulators may consider licensure
based on serological endpoints if determined to be reasonably
likely to predict clinical benefit. In the case of the FDA, this may
lead to an accelerated approval pathway, which requires post-
licensure studies to verify and describe clinical benefit [50]. Irre-
spective of the licensure pathway, policy decision and the adoption
of a vaccine into a public health programme will likely require
demonstration of both safety and clinical benefit.
Adequate safety profile characterization is paramount. Standard
case definitions for outcomes of relevance to maternal immuniza-
tion including infant outcomes will be important. In this context,
recent efforts by the Global Alignment of Immunization Safety
Assessment in pregnancy (GAIA) working group coordinated by
the Brighton Collaboration Foundation should prove useful [51].
Pre-licensure studies will likely be required to demonstrate that
maternal immunization does not adversely interfere with an
infant’s response to other relevant vaccines, due to the transfer
of maternal antibodies to the carrier proteins. Co-administration
studies with other vaccines recommended for maternal immuniza-
tion may also be important.
8. Considerations for phase III trials
A phase III trial with a primary clinical disease endpoint would
provide the most compelling evidence of efficacy, and should
include a nested immunogenicity study to allow for evaluation of
correlates of protection.
Culture-confirmed invasive GBS disease in young infants would
likely meet regulatory requirements for a primary endpoint. This is
a clinically relevant endpoint of public health relevance that can be
defined with high specificity. Similar clinical endpoints have been
used in trials to support the licensure of other conjugate vaccines.
Since blood culture positivity rates vary according to the clinical
criteria guiding sample collection, as well as sample quantity,
quality and processing methods (e.g., manual vs. automated blood
culture), standardization of these procedures across trial sites
will be needed. Use of molecular tests, such as PCR, might help
increase sensitivity, but further data are needed to assess the
impact on specificity of the endpoint case definition. Because
GBS-associated stillbirths can be considered as a continuum of
neonatal GBS disease due to their similar pathophysiology, consid-
eration should be given to the inclusion of GBS-confirmed still-
births with young infant disease as part of a composite disease
endpoint. Two recent studies in Kenya [21] and South Africa
[Madhi et al., in progress] that collected sterile site samples from
stillbirths for identification of GBS may provide a foundation
for the development of standardized case definitions for
GBS-associated stillbirths.
A key issue for GBS vaccines is the possibly low baseline inci-
dence of the primary endpoint of invasive disease, requiring phase
III clinical efficacy trials to be very large. For example, in a popula-
tion with a baseline incidence of GBS invasive disease of 2.0 per
1000 live births, assuming a proportion of cases are not eligible
for endpoint inclusion and assuming a 75% vaccine efficacy, a trial
size of 40,000–60,000 mother-baby dyads would be required [52].
Such high sample size requirements would pose both logistic and
cost issues. Having a composite disease endpoint, for example
including both GBS-related stillbirth and invasive GBS disease in
neonates and young infants, would reduce the required trial size.
Other considerations in trial design and trial site selection
include: the availability of reliable baseline incidence data; preva-
lence of underlying conditions that could affect the immune
response to vaccination, such as HIV; home-delivery rates (consid-
ering that most EOD occurs during the first 24 h of life); diagnostic
capacity for both safety and efficacy evaluation; capacity to assess
sepsis and gestational age; barriers to access to care; Good Clinical
Practice research experience; and national regulatory and local
ethical review capacity.
In settings with very low baseline GBS-related disease incidence
in the context of optimal preventive care, conducting an efficacy
trial of a GBS vaccine may not be feasible. However, in high GBS
burden settings where universal screening during pregnancy is
not the local standard of care and IAP is not effectively imple-
mented, a placebo-controlled vaccine trial, without introducing
screening-based IAP, could be considered ethically acceptable
[53]. Lack of post-trial sustainability, the possible creation of a dou-
ble standard of care in the same community and the possibility of
undue inducement to study participation were seen as arguments
against the specific implementation of screening-based IAP in a
phase III trial in many LMIC settings. Locally-approved criteria
for antibiotic treatment initiation should be defined in standard
operating procedures, delineating essential needs for antenatal
care, delivery, and postnatal care, following national guidelines
when available, considering WHO recommendations and the local
context. Samples for bacterial cultures from potential cases should
be obtained before antibiotic administration, which should be doc-
umented, in line with the 2013 WHO recommendation for postna-
tal empiric antibiotics for high-risk infants [16].
It is critical that host countries and trial communities are appro-
priately engaged in the planning and conduct of pre-licensure trials
and in vaccine implementation plans after successful licensure and
recommendations for use. Trials should be conducted only in set-
tings where there is an intent to introduce a vaccine shown to be
efficacious.
The characterization of a correlate of protection would be of
high-value, especially for bridging studies in different population
groups. It is unclear the extent to which correlates of protection
may be inferred from the evaluation of natural immunity in obser-
vational studies. In this respect, it will be important to assess the
equivalence between GBS antigen-specific IgG concentrations and
functional antibody levels in naturally immunized versus vacci-
nated subjects. In addition, correlates of protection may vary by
serotype and by disease entity.
There is an urgent need for standardized assays, to support
between-study comparisons and bridging studies, with
4 M. Kobayashi et al. / Vaccine xxx (2016) xxx–xxx
Please cite this article in press as: Kobayashi M et al. WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–
28 April 2016. Vaccine (2016), http://dx.doi.org/10.1016/j.vaccine.2016.12.029
regulatory-acceptable quality systems, both for serological anti-
body binding assays such as enzyme-linked immunosorbent assays
(ELISA) and functional assays such as opsonophagocytic activity
(OPA) assays that measure bacterial killing. GBS assay standardiza-
tion initiatives are ongoing. Keys to success in standardizing pneu-
mococcal assays included: (1) involvement of manufacturers and
regulators from the outset; (2) willingness of laboratories to adjust
their protocols; (3) availability of a central source of relevant
reagents, such as reference sera, antigen sources, bacterial strains;
and (4) established WHO reference laboratories as part of WHO’s
Collaborating Centre networks. It will be very helpful to include
laboratories with previous experience working with WHO, and
regulators and manufacturers with previous experience of conju-
gate vaccine approaches (bearing in mind, also, possible protein
approaches to vaccine development). Pfizer and GSK are exploring
the possibility to supply unconjugated GBS CPS to a GBS consor-
tium through a third party, such as the UK National Institute for
Biological Standards and Control.
Maternal or newborn colonization may potentially serve as a
secondary endpoint in phase III trials, given that newborn GBS col-
onization or exposure from colonized mothers is a precursor to
young infant invasive GBS disease. An early serotype III conjugate
vaccine candidate tested in non-pregnant women indeed showed
reduced rates of acquisition of type-specific GBS colonization
[54]. Colonization was not viewed, however, as a potential licen-
sure endpoint based on the view that efficacy against colonization
may not necessarily reflect efficacy against disease, as virulence
and other factors may influence whether colonization leads to
invasive disease, and circulating antibodies may prevent invasive
disease but not colonization [55].
There was general agreement that it would not be reasonable to
expect that a phase III study be powered to produce CPS serotype-
specific efficacy estimates. Post-licensure evaluations will play a
critical role in characterizing rarer safety events than are detect-
able in a phase III trial and effectiveness under ‘‘real-world” condi-
tions, as well as in special populations of interest or for obtaining
serotype-specific results. Post-licensure monitoring should include
surveillance for capsular switching and serotype replacement, as
has been observed with pneumococcus. The safety requirements
and possibility of emergence of escape variants should also be con-
sidered for protein vaccines, given that there are sequence
polymorphisms.
9. Gaps and next steps
In September 2015, PDVAC recommended that WHO develop
guidance on development pathways for GBS vaccines [1]. While
the April 2016 GBS consultation convened by WHO was an impor-
tant step, the need, as PDVAC highlighted, for consensus on strate-
gic goals, trial design considerations and development of preferred
product characteristics remains critical and should be addressed in
the near term. WHO will progress towards the publication of a GBS
vaccine development roadmap. Work to address several key
knowledge gaps (Table 1), particularly efforts underway to update
global disease burden estimates, and to standardize immunological
assays, will maintain momentum and facilitate preparation for
phase III trials. Participants highlighted several additional areas
for research that can be of value in parallel with product develop-
ment, including: assessments of pregnant women and healthcare
worker attitudes and concerns regarding maternal immunization
in LMICs; efforts to raise awareness of the burden of GBS disease
and to sensitize the public health community about the potential
value of a GBS vaccine, particularly in countries that may lack local
data on the GBS burden; synthesizing lessons from experience
with maternal immunization in LMICs against influenza, tetanus
and pertussis and identifying any synergies with newly launching
efforts related to maternal RSV immunization; and identifying
likely routes for maternal immunization financing for LMIC, partic-
ularly as more countries in sub-Saharan Africa and Southeast Asia
transition from eligibility for GAVI financing to partial or full self-
financing.
Beyond licensure considerations, it is also important to con-
sider, at an early stage, strategies to reduce the time between licen-
sure and vaccine deployment in LMICs [56]. Support from United
Nations procurement agencies and GAVI funding require both
WHO prequalification and policy recommendation (through
WHO Strategic Advisory Group of Experts (SAGE) on Immuniza-
tion) [57]. Such policy recommendations depend on additional fac-
tors beyond those considered during regulatory review, including
implementation feasibility, impact on health systems, integration
with other interventions and cost-effectiveness. Advance planning
for provision of key evidence may help shorten the interval
between regulatory approval and implementation scale-up [58].
Successful licensure and implementation of RSV vaccines,
which are at a more advanced stage of development, may help fill
key implementation evidence gaps and strengthen the maternal
immunization platform, laying the groundwork for a rapid rollout
of a GBS maternal immunization programme once a safe and effec-
tive vaccine is approved by national regulatory authorities and rec-
ommended for use by policy makers.
Meeting attendees
Participants: Mark Alderson (PATH, Seattle, USA), Carol J. Baker
(Baylor College of Medicine, Houston, USA), Azucena Bardaji (Man-
hica Health Research Centre, Mozambique and ISGlobal, Barcelona,
Spain), Hellen Cherono Barsosio (KEMRI-Wellcome Trust Research
Programme, Kilifi, Kenya), Jay Berkley (KEMRI-Wellcome Trust
Research Programme, Kilifi, Kenya), Adriane de Oliveira (Agência
Nacional de Vigilância Sanitária, Brasilia, Brazil), Andrew Gorringe
(Public Health England, Porton Down, UK), Ruth Gilbert (Institute
of Child Health, London, UK), David Goldblatt (University College
London Medical School, London, UK), Paul T. Heath (Vaccine Insti-
tute, St Georges, University of London, London, UK), Philip Henneke
(Center for Pediatrics and Center for Chronic Immunodeficiency,
University Medical Centre, Freiburg, Germany), Margaret Ip (Chi-
nese University of Hong Kong, Hong Kong, China), Beate Kamp-
mann (MRC, Banjul, Gambia), Eric Karikari-Boateng (Food and
Drugs Board Ghana, Accra, Ghana), David Kaslow, PATH, Seattle,
USA), John Kinuthia (Kenyatta National Hospital, Kilifi, Kenya),
Miwako Kobayashi (Centers for Disease Control and Prevention,
Atlanta, USA), Gaurav Kwatra (WITS University, Johannesburg,
South Africa), Bengt Johansson Lindbom (Lund University, Swe-
den), Shabir A. Madhi (National Institute for Communicable Dis-
eases, Johannesburg, South Africa), Fatme Mawas (NIBSC, MHRA,
Potters Bar, UK), Kirsty Mehring-Le Doare (Imperial College Faculty
of Medicine, London, UK), Malcolm Molyneux (Liverpool School of
Tropical Medicine, Liverpool, UK), Moon Nahm (University of Ala-
bama at Birmingham, Birmingham, USA), Patricia Njuguna
(KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya), Ste-
ven K. Obaro (University of Nebraska Medical Center, Omaha
Nebraska, USA), Eric Pelfrene (European Medicines Agency, Lon-
don, UK), Fernando Polack (Fundación INFANT, Buenos Aires,
Argentina), Adam Ratner (New York University School of Medicine,
New York, USA), Laura Riley (Massachusetts General Hospital, Bos-
ton, USA), Jeff Roberts (Food and Drug Administration, Silver
Spring, USA), Samir Saha (Institute of Child Health, Dhaka, Bangla-
desh), Stephanie Schrag (Centre for Disease Control and Preven-
tion, Atlanta, USA), Anna Seale (London School of Hygiene and
Tropical Medicine, London, UK), Betuel Sigaúque (Centro de Inves-
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Table 1
Knowledge gaps, areas for further research.
Topic Knowledge gaps, areas for research
GBS pathophysiology Pathophysiology of GBS-associated disease and conditions
 Factors determining progression from colonization to LOD
 Progression from maternal colonization to ascending infection and stillbirth
 Relationship between maternal colonization and preterm births
 Differential risk factors for LOD compared to EOD
GBS epidemiology in LMICs Young infant disease
 Preterm contribution to young infant disease burden, particularly in LMICs where preterm survival may be lower
 LOD epidemiology in LMICs
 Understanding differences from that described in HICs (e.g., proportion preterm, ratio of early to late-onset
disease, median age of onset, role of maternal HIV infection)
 Role of socio-economic status, urbanization, and birth location (facility type, home vs facility) in GBS disease risk
GBS-associated stillbirth
 Risk factors associated with GBS-associated stillbirth
GBS disease burden Surveillance challenges
 Lack of specimens from ill newborns in high neonatal mortality settings
 Failure to obtain specimens in the first days of life
 Limited sensitivity of cultures used to detect disease
 Difficulty in isolating and characterizing GBS from colonized specimens
 Collection of denominator data for incidence estimates
Young infant disease burden
 More information on burden from LMICs, especially South Asia
 Sub-Saharan Africa: representation beyond southern Africa
 Areas with low maternal HIV
 Low-income countries (LICs)
 More evidence on disease burden from other high mortality regions
 More comprehensive serotype and protein type diversity data from LMICs, especially LICs
Pregnancy-associated disease burden
 Limited information from LMICs
GBS-associated stillbirth burden
 Need for a standardized definition
 Challenges in obtaining appropriate specimens
Non-pregnant adults
 Limited information from LMICs
GBS disease management and prevention
practices
Knowledge gaps related to perinatal care in LMIC
 Current status of ANC visit uptake in LMICs (as a potential maternal vaccine delivery channel)
 Status of implementation of WHO-recommended perinatal care in LMICs
 Understanding the challenges associated with IAP implementation in LMICs
Getting a product to phase III Universal gaps
 Reproductive toxicity animal model validation
 Assay standardization
 Establishing correlates of protection
 Ascertaining appropriate window during pregnancy for vaccination to achieve optimal antibody transfer to the
newborn
 Assessment of immune interference with other maternal and infant vaccines
Conjugate vaccines
 Immunogenicity and safety data on higher-valency candidate vaccines
 Ascertainment of whether a single dose elicits adequate immune response, especially in women without detectable
baseline antibody and in women with HIV infection
Protein vaccines
 Safety and immunogenicity data in pregnant women
 Assessment of whether an adequate immune response can be achieved by a single-dose and whether adjuvant is
required
 Foundational work on correlates of protection and appropriate immunogenicity assays pending
GBS vaccine development considerations for
LMICs
 Strengthen dual vaccine development pathway (for use in both HICs and LMICs)
 Need for a mechanism to support vaccine development in LMICs
 Supporting LMIC manufacturers
 Supporting local regulatory authorities
 Limited assessment on cost-effectiveness for LICs (one for sub-Saharan Africa in progress)
Regulatory considerations Acceptable licensure pathways
 Clarification of conditions where a substitute endpoint for clinical disease (for example an immune correlate of
protection) may be acceptable for licensure
 Clarification of pathways for generalizing results across the different settings where vaccine may be used
Planning for phase III trials Consensus building
 GBS maternal immunization strategic objectives
 Preferred product characteristics
 Licensure trial design considerations, including case definitions and disease endpoints
 Flexible clinical development pathway options, depending on generated evidence
Study site preparation
 Study site selection
 Development of study standard operating procedures and capacity for trial implementation
Preparing for post-licensure needs to
facilitate implementation
Building stakeholder commitment
 Characterize concerns regarding maternal immunization among pregnant women and healthcare workers
 Increase awareness about GBS disease
 Sensitize the public health community about the potential value of a GBS vaccine
Minimizing the evidence gap for implementation
 Advanced planning to support a SAGE policy recommendation and WHO prequalification
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